Pitch for Investment

Latest Insights, Interviews, News, and Resources.

The latest news from UKI2S and our portfolio companies

Circuit

Eagle Genomics Gains Microsoft Co-Sell Status for Microbiome Mapping AI Platform

13th September 2018

Eagle Genomics has landed a prestigious co-sell partnership with Microsoft for their knowledge discovery platform.

Suited

Crescendo Biologics Strengthens its Management with the Appointment of Dr Pavel Pisa as Chief Medical Officer

11th September 2018

Crescendo Biologics Ltd (Crescendo), the drug developer of novel, targeted T-cell enhancing therapeutics, today announces that Pavel Pisa, MD, PhD, has been appointed as…
Shop window

Eagle Genomics Lands Co-Sell Status as Part of Microsoft for Startups Programme

5th September 2018

Eagle Genomics joins a specialised group of high-growth startups, earning co-sell status as part of Microsoft’s new programme to collaborate on intensive joint sales and go-to-market initiatives.
Eye closeup

Astellas Announces Acquisition of Quethera

10th August 2018

Acquisition furthers Astellas’ commitment to innovation in ophthalmology with addition of novel gene therapy program for glaucoma.
Medication

UKI2S announces seed investment in Cagen, a pioneering engineering biology company using protein nanocages

10th August 2018

UK Innovation & Science Seed Fund (UKI2S) and Imperial Innovations announce the launch of Cagen, a company focused on innovative uses of protein nanocages.
Banana

Scientists scramble to stop bananas being killed off

18th July 2018

British firm Tropic Bioscience races to produce bananas resistant to fungus sweeping global plantations.
Medication

CellCentric raises $26m for new late-state prostate cancer drug

16th July 2018

UKI2S biotech company CellCentric, University of Cambridge spinout, has raised $26m to fund clinical testing of its first-in-class oncology drug candidate, CCS1477.
Computer Code

Synthace Named a 2018 Cool Vendor in Life Sciences by Gartner

20th June 2018

Recognised by Leading Analyst Firm for its Laboratory of the Future Platform.
Seminar

UKI2S Portfolio Company Marketing Seminar

23rd May 2018

Watch the video.
Medication

CellCentric raises $26 million to take first-in-class p300/CBP inhibitor into the clinic

15th May 2018

CellCentric has raised $26 million in private financing to fund clinical testing of its first-in-class oncology drug candidate CCS1477.

Taking notes

Eagle Genomics raises $1m in funding first close and announces senior leadership changes

3rd May 2018

Software leader in the field of genomic data and bioinformatics analysis poised for growth.
ATELERIX LTD

Atelerix Raises Seed Round

2nd May 2018

Cell encapsulation start-up enables the shipment of human cells at room temperature, overcoming problems of cryo-shipping.
Mirico Team Oxford UK

MIRICO Secures £3.5 Million Venture Backing

30th April 2018

STFC spin-out  pioneering new generation of laser gas-sensing solutions.
Lab work

UK biotech to manufacture novel medicines for Inflammatory Bowel Disease using spores of gut bacteria

27th March 2018

Three leading British biotechnology businesses have obtained grant funding from Innovate UK to investigate the manufacture of a new class of medicines…
Money

Funding New Spinouts & Backing an Industry Leader

14th March 2018

We work closely with our partner laboratories to identify commercial opportunities arising from their world-class research and we are excited to announce investments in…
Glialign CEO John Sinden

UCL Technology Fund and UK Innovation & Science Seed Fund invest in cell therapy company Glialign

11th March 2018

The UCL Technology Fund (UCLTF), UK Innovation & Science Seed Fund (UKI2S), alongside support from Innovate UK, have invested in UCL spinout company Glialign Ltd…
Synthace research

CellCentric’s first-in-class p300/CBP inhibitor drug CCS1477; capsule production complete ready for the clinic

8th March 2018

Production of CCS1477 in capsule form is now complete, ahead of forthcoming first-in-human clinical trials to investigate the novel drug’s tolerability and efficacy…
Money

Early Stage Science Companies Secure Investment

7th March 2018

The UK Innovation & Science Seed Fund (UKI2S) – formerly known as Rainbow Seed Fund – has invested via Innovate UK’s £8.5m accelerator, which combines equity and grant funding.
Crescendo

UK Innovation & Science Seed Fund Backs First Early-Stage Science Ventures in Partnership with Innovate UK

6th March 2018

First science companies funded from investment accelerator pilot that joins grant funding with venture capital to help bridge the gap between UK R&D and commercialisation.
johannes plenio

Rainbow Seed Fund Changes Name to UK Innovation Science & Seed Fund

30th January 2018

In recognition of our Fund’s widening reach to build world-leading companies from world-leading UK science, as of January 2018, we have changed our name…
Ian Taylor speaks about patient capital investment

The UK Innovation Ecosystem – Patient Capital’s Role for the UK’s Science Ventures

6th December 2017

UK Innovation & Science Seed Fund  is a patient capital investor in ideas emerging from the UK’s publicly-funded science base. We are now collaborating with the Innovate UK’s Catapult Network. In recognition of our widening scope, ambition and remit, from the start of 2018, UKI2S will be renamed UK Innovation & Science Seed Fund (UKI2S)….

Pireta

UK Innovation & Science Seed Fund Backs Pireta

23rd October 2017

A Smart Textiles Technology Developed at the National Physical Laboratory.
Crescendo

UKI2S’ Success Working with Innovate UK Accelerator Program

6th October 2017

UK Innovation & Science Seed Fund has closed its first investment (to be announced soon) originating from the Fund’s participation in the Innovate UK (IUK) Investment Accelerator pilot…
Test Tubes

£160m funding boost for British life sciences

14th September 2017

Investing in the UK life science ecosystem.
UKI2S

© UKI2S and Future Planet Capital (Ventures) Limited. All Rights Reserved. UKI2S is managed by Future Planet Capital (Ventures) Limited which is Authorised and Regulated in the UK by the Financial Conduct Authority FRN 148549. Registered in England and Wales. Company Number 2500898. Registered Address: Future Planet Capital (Ventures) Limited, t/a Midven, 1 Scott Place, 2 Hardman Street, Manchester, M3 3AA.

Stay updated